The New England Journal of Medicine July 04, 2019

Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer

Kim N. Chi, Neeraj Agarwal, Anders Bjartell et al.

Bottom Line

In patients with metastatic, castration-sensitive prostate cancer, the addition of apalutamide to androgen-deprivation therapy significantly prolonged both radiographic progression-free survival and overall survival compared to placebo.

Key Findings

1. At a median follow-up of 22.7 months [3.3.1], apalutamide significantly reduced the risk of radiographic progression or death by 52% compared to placebo (HR 0.48; 95% CI, 0.39 to 0.60; P<0.001).
2. The 24-month radiographic progression-free survival rate was 68.2% in the apalutamide group versus 47.5% in the placebo group.
3. Apalutamide significantly improved overall survival, reducing the risk of death by 33% (HR 0.67; 95% CI, 0.51 to 0.89; P=0.005).
4. The 24-month overall survival rate was 82.4% in the apalutamide group versus 73.5% in the placebo group.
5. Adverse events that were more common with apalutamide included rash (27.1% vs. 8.5%), hypothyroidism (8.1% vs. 2.0%), and ischemic heart disease (4.4% vs. 1.5%), though overall health-related quality of life was maintained.

Study Design

Design
Phase 3 RCT
Double-Blind
Sample
1,052
Patients
Duration
22.7 mo
Median
Setting
Multicenter, global
Population Men with metastatic, castration-sensitive prostate cancer (mCSPC) receiving ongoing ADT. Prior docetaxel and prior treatment for localized disease were permitted.
Intervention Apalutamide (240 mg daily) plus ADT
Comparator Placebo plus ADT
Outcome Radiographic progression-free survival (rPFS) and overall survival (OS)

Study Limitations

The initial overall survival analysis was based on a relatively short median follow-up of 22.7 months, though follow-up updates would later confirm the sustained benefit.
Only 10.7% of the enrolled patients had received prior docetaxel therapy, limiting the statistical power to draw definitive conclusions about the incremental efficacy of apalutamide in this specific, heavily pre-treated subgroup.
Long-term safety outcomes regarding cumulative toxicities of direct androgen receptor inhibition, particularly cardiovascular events and bone fractures, require extended follow-up.

Clinical Significance

The TITAN trial demonstrated that the addition of apalutamide to standard androgen-deprivation therapy (ADT) provides significant, concurrent benefits in both overall and radiographic progression-free survival for men with metastatic castration-sensitive prostate cancer (mCSPC). The consistent benefit observed across patients regardless of disease volume (low or high) or prior local treatments established apalutamide as a foundational, first-line standard of care option for mCSPC, resulting in its global regulatory approval.

Historical Context

Historically, metastatic castration-sensitive prostate cancer (mCSPC) was treated almost exclusively with androgen deprivation therapy (ADT) alone, leading inevitably to castration-resistant disease. The CHAARTED and STAMPEDE trials radically altered the paradigm by demonstrating a survival benefit with the early addition of docetaxel for high-volume disease. Subsequently, LATITUDE and STAMPEDE showed that early integration of abiraterone acetate was highly effective. The TITAN trial, published concurrently with the ENZAMET trial, expanded this modern paradigm by confirming that next-generation, direct androgen receptor inhibitors like apalutamide offer substantial survival benefits and provide a well-tolerated alternative to chemotherapy or abiraterone when added upfront to standard ADT.

Guided Discussion

High-yield insights from every perspective

Med Student
Medical Student

What is the mechanism of action of apalutamide compared to traditional androgen deprivation therapy (like leuprolide), and why might combining them be synergistic in castration-sensitive prostate cancer?

Key Response

Leuprolide is a GnRH agonist that suppresses testicular androgen production, but adrenal glands and tumor cells can still synthesize androgens. Apalutamide directly antagonizes the androgen receptor (AR) by binding to its ligand-binding domain, preventing nuclear translocation and DNA binding. Combining them achieves a more complete blockade of the androgen axis, preventing tumor growth driven by non-testicular androgens.

Resident
Resident

A 65-year-old patient with newly diagnosed high-volume metastatic castration-sensitive prostate cancer is starting ADT. Based on the TITAN trial and similar studies, what factors would guide your choice between adding apalutamide, abiraterone, or docetaxel to his regimen?

Key Response

The choice depends on comorbidities, toxicity profiles, and disease volume. Apalutamide is effective regardless of disease volume but can cause rash and falls. Abiraterone requires concurrent prednisone, making it less ideal for patients with poorly controlled diabetes or heart failure. Docetaxel is an option for high-volume disease in fit patients who prefer a defined, shorter course of treatment rather than continuous novel antiandrogen therapy.

Fellow
Fellow

The TITAN trial included patients who had previously received docetaxel for mCSPC. How does prior docetaxel exposure impact the efficacy of apalutamide in this setting, and what does this suggest about cross-resistance mechanisms between taxanes and androgen receptor signaling inhibitors?

Key Response

Subgroup analyses in TITAN suggested that patients with prior docetaxel still benefited from apalutamide, though the hazard ratio for OS often has wider confidence intervals in this smaller subgroup. Taxanes not only disrupt microtubules but also impair AR nuclear transport. Understanding whether sequential AR-targeted therapy after chemotherapy retains full efficacy is crucial for sequencing, especially as mechanisms like AR-V7 splice variants can mediate resistance to AR inhibitors but may not preclude taxane efficacy.

Attending
Attending

Given the significant OS benefit demonstrated in trials like TITAN (apalutamide), LATITUDE (abiraterone), and ENZAMET (enzalutamide), is there any remaining role for ADT monotherapy in metastatic castration-sensitive prostate cancer, and how do you counsel patients on the toxicities of treatment intensification?

Key Response

ADT monotherapy is no longer the standard of care for mCSPC unless the patient has severe life-limiting comorbidities or absolute contraindications to treatment intensification. The teaching point is that intensification is the new standard. Counseling must balance the undeniable survival benefits against the financial toxicity of continuous AR-targeted therapies and quality-of-life impacts like fatigue, cognitive changes, and fracture risk.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD
PhD

The TITAN trial utilized a dual primary endpoint design (rPFS and OS) with alpha-splitting to control the family-wise error rate. What are the statistical advantages and potential pitfalls of this hierarchical testing approach in oncology trials compared to using a single primary endpoint with subsequent sequential testing?

Key Response

Dual primary endpoints allow a trial to be declared positive if either endpoint meets its allocated alpha threshold, increasing the chance of early regulatory approval (e.g., via rPFS) while still powering for the definitive endpoint (OS). However, it requires careful alpha allocation to preserve the overall Type I error rate. A major pitfall is that early stopping for an intermediate endpoint like rPFS can lead to treatment crossover, potentially confounding the mature OS analysis.

Journal Editor
Journal Editor

In the TITAN trial, placebo patients were allowed to cross over to the apalutamide arm upon unblinding after the first interim analysis showed a significant rPFS benefit. As an editor, how do you evaluate the impact of this crossover on the mature overall survival data, and what statistical methods should the authors use to adjust for this confounding?

Key Response

Ethical mandates require crossover when a highly effective therapy is identified, but this dilutes the OS benefit because intention-to-treat analysis biases toward the null. A critical reviewer would look for robust pre-specified adjustment methods, such as Inverse Probability of Censoring Weighting (IPCW) or Rank Preserving Structural Failure Time (RPSFT) models, to estimate the true OS effect had the crossover not occurred, ensuring the long-term survival claims remain statistically valid.

Guideline Committee
Guideline Committee

Based on the Category 1 evidence from the TITAN trial, how should clinical guidelines formally integrate apalutamide alongside abiraterone, enzalutamide, and docetaxel for mCSPC, and what specific patient characteristics should guidelines highlight to differentiate the preferred use of these agents?

Key Response

Apalutamide received a strong recommendation for mCSPC based on TITAN. Current NCCN and EAU guidelines recommend ADT plus either an AR pathway inhibitor or docetaxel. Guidelines should emphasize that unlike LATITUDE (which focused on high-risk disease), TITAN included all-comers (high and low volume). Guidelines must delineate choice based on toxicity: apalutamide avoids the steroid requirement of abiraterone but requires monitoring for rash, falls, and thyroid dysfunction, facilitating individualized shared decision-making.

Clinical Landscape

Noteworthy Related Trials

2015

CHAARTED Trial

n = 790 · NEJM

Tested

Docetaxel plus Androgen-Deprivation Therapy (ADT)

Population

Men with metastatic hormone-sensitive prostate cancer

Comparator

ADT alone

Endpoint

Overall survival

Key result: Adding docetaxel to ADT significantly improved overall survival, particularly in patients with high-volume disease.
2017

LATITUDE Trial

n = 1199 · NEJM

Tested

Abiraterone acetate plus prednisone and ADT

Population

Men with newly diagnosed high-risk metastatic castration-sensitive prostate cancer

Comparator

Placebo plus ADT

Endpoint

Overall survival and radiographic progression-free survival

Key result: Abiraterone plus ADT significantly improved overall survival and radiographic progression-free survival compared to ADT alone.
2019

ARCHES Trial

n = 1150 · JCO

Tested

Enzalutamide plus ADT

Population

Men with metastatic hormone-sensitive prostate cancer

Comparator

Placebo plus ADT

Endpoint

Radiographic progression-free survival

Key result: Enzalutamide plus ADT significantly reduced the risk of radiographic progression or death compared with ADT alone.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis